Skip to content
TrialScanner

NCT06052852

Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

Phase 1TerminatedBOLTLeadREGNCollaborator

Registry record

Lead sponsor
Bolt Biotherapeutics, Inc.
Conditions
Triple Negative Breast Cancer; Clear Cell Renal Cell Carcinoma; Ovarian Cancer; Head and Neck Cancer; Colorectal Cancer
Primary completion
Aug 1, 2025Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT06052852 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT06052852: Study of BDC-3042 as Single... | TrialScanner